AMEFX
Price
$24.75
Change
-$0.13 (-0.52%)
Updated
Dec 17 closing price
RIDFX
Price
$24.78
Change
-$0.13 (-0.52%)
Updated
Dec 17 closing price
Ad is loading...

AMEFX vs RIDFX

Header iconAMEFX vs RIDFX Comparison
Open Charts AMEFX vs RIDFXBanner chart's image
American Funds Income Fund of Amer F2
Price$24.75
Change-$0.13 (-0.52%)
VolumeN/A
CapitalizationN/A
American Funds Income Fund of Amer R5
Price$24.78
Change-$0.13 (-0.52%)
VolumeN/A
CapitalizationN/A
AMEFX vs RIDFX Comparison Chart
Loading...
View a ticker or compare two or three
VS
AMEFX vs. RIDFX commentary
Dec 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMEFX is a Buy and RIDFX is a Buy.

FUNDAMENTALS
Fundamentals
AMEFX (123B) and RIDFX (123B) have equal amount of cash in the bank . RIDFX (3.78) and AMEFX (3.73) have matching dividends . AMEFX was incepted earlier than RIDFX: AMEFX (16 years) vs RIDFX (23 years). AMEFX (40.00) and RIDFX (40.00) have comparable annual turnover. AMEFX (250) and RIDFX (250) have matching initial minimum investment requirements. RIDFX (10.92) and AMEFX (10.88) have marching annual gain over last year. RIDFX (21.29) and AMEFX (21.04) have equivalent 5 years return.
AMEFXRIDFXAMEFX / RIDFX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence16 years23 years-
Gain YTD9.5089.550100%
Front LoadN/AN/A-
Min. Initial Investment250250100%
Min. Initial Investment IRAN/AN/A-
Net Assets123B123B100%
Annual Yield % from dividends3.733.7899%
Returns for 1 year10.8810.92100%
Returns for 3 years6.576.6998%
Returns for 5 years21.0421.2999%
Returns for 10 years33.7634.1999%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MLTX56.303.32
+6.27%
MoonLake Immunotherapeutics
CVKD11.450.45
+4.09%
Cadrenal Therapeutics Inc
CMPX1.530.04
+2.68%
Compass Therapeutics
WAT373.72-0.29
-0.08%
Waters Corp
PSTX9.50-0.01
-0.11%
Poseida Therapeutics